DYADIC INTERNATIONAL INC Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
DYADIC INTERNATIONAL INC (DYAI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $2.42 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- DYADIC INTERNATIONAL INC share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.62.
- DYADIC INTERNATIONAL INC share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.95, a 20.37% increase year-over-year.
- DYADIC INTERNATIONAL INC share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.62, a 76.42% decline year-over-year.
- DYADIC INTERNATIONAL INC share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2022-03-31 was $6.87.
- DYADIC INTERNATIONAL INC share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $2.99, a 38.43% increase from fiscal 2024.
- DYADIC INTERNATIONAL INC share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $2.16, a 26.32% increase from fiscal 2023.
- DYADIC INTERNATIONAL INC share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $1.71, a 68.74% decline from fiscal 2022.
- DYADIC INTERNATIONAL INC share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $5.47.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.42 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $1.62 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $2.99 10-K · filed 2026-03-25 | |||
| 2024-12-31 | $2.16 10-K · filed 2026-03-25 | |||
| 2024-09-30 | $2.10 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $2.10 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $1.95 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $1.71 10-K · filed 2025-03-26 | |||
| 2023-09-30 | $1.62 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $1.62 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $1.62 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $5.47 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $6.22 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $6.87 10-Q · filed 2022-08-10 | |||
| 2022-03-31 | $6.87 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-29 | |||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-29 | |||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-13 | |||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-14 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-30 | |||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-13 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-13 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $0.00 10-K · filed 2020-03-30 | |||
| 2016-12-31 | $1.33 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |